Tempest TPST-1120 achieves 30% ORR vs 13.3% control in randomized HCC study; adopts poison pill

Tempest Therapeutics, Inc.

Confirmed ORR 30% for TPST-1120 arm vs 13.3% control; duration of response not reached.
PFS HR 0.7 (median 7 mo vs 4.27 mo); OS HR 0.59 (median not reached vs 15.1 mo).
In beta-catenin mutation patients, cORR 43% and DCR 100%; in PD-L1 negative, cORR 27% vs 7% control.
Adopted limited duration rights plan; triggers at 10% (15% passive); expires Oct 2024 or 2026 if approved.
40% of TPST-1120 arm patients remain on treatment vs 16.7% control; safety comparable between arms.

item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tempest Therapeutics, Inc. entered into Rights Agreement with Computershare Trust Company, N.A. (effective 2023-10-10).

Action: entry
Counterparty: Computershare Trust Company, N.A.
Effective: 2023-10-10

Exact text from the filing

the Rights Agreement, dated as of October 10, 2023 (the “Rights Agreement”), by and between the Company and Computershare Trust Company, N.A., as Rights Agent

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-253882

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.